In Brief: FDA Orthopedic and Rehabilitation Devices Panel
This article was originally published in The Gray Sheet
FDA Orthopedic and Rehabilitation Devices Panel: Agenda for Jan. 12-13 meeting at FDA's Parklawn Building in Rockville, Maryland has been rearranged with discussion of a reclassification petition for constrained elbows moved up one day to Jan. 12, along with originally scheduled petitions for non-and semi-constrained shoulders. Renew of petitions for patellofemoral knees and uni- and total patellofemorotibial knees has been rescheduled from Jan. 12 to Jan. 13, alongside the originally planned discussion of the classification of calcium sulfate pre-formed pellets (plaster of paris pellets). Contact panel secretary Jodi Nashman at 301/594-2036 for further information...
You may also be interested in...
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.